Nanotherapeutics exhibit major benefits with respect to unmodified drugs, including improved half-life, more efficient tumor targeting, and reduced side effects. Our expertise in pathophysiological disease modeling, functional validation and therapeutic target discovery supports different national and international projects at the early stage of development of new nanotherapeutics.

We utilize nanotechnology expertise to develop molecular intraoperative diagnostics or theranostics to advance and complement minimal invasive surgery. MES is core group member of the organization committee the European Union funded network Nano2Clinic.